10-Q quarterly report · filed Nov 12, 2026

SELLAS Life Sciences Group, Inc. (SLS) Q3 2026 10-Q Quarterly Report

Short answer

SELLAS Life Sciences Group, Inc. (SLS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$10M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$10M
−48.6% YoY · −5.1% QoQ
EPS (diluted)
−$0.05
+28.6% YoY · +0.0% QoQ

Source: XBRL data from the SELLAS Life Sciences Group, Inc. (SLS) Q3 2026 10-Q on SEC EDGAR. USD.

SELLAS Life Sciences Group, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0 from product sales in nine months ended September 30, 2026, unchanged YoY
  • Net loss $10.1M vs $6.8M YoY, operating loss $11.3M vs $7.1M
  • SLS009 strongest clinical results: 34% ORR all doses, 54% monocytic AML at selected dose
  • Cash and equivalents $134.7M plus restricted cash $0.1M, warrant exercises generated $85.1M
  • Outlook: cash sufficient for at least twelve months, Phase 2 enrollment ongoing, REGAL topline results expected November 2026

Risk Factors

  • No material changes disclosed from the 2025 Annual Report
  • Clinical-stage biotechnology risk: Additional unknown risks could materially harm business, financial condition, results, or stock price
  • Forward-looking statement risk: Projections remain subject to uncertainties incorporated by reference
  • Stock-price risk: Undisclosed or currently immaterial risks could adversely affect valuation

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other SELLAS Life Sciences Group, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.